Evopoint Biosciences

Evopoint Biosciences is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the discovery and development of innovative therapies for oncology, infectious diseases, and metabolic disorders. Formerly known as Sinovent, the company has transitioned into a platform-based organization leveraging three core technology pillars: Small Molecule Discovery, Novel Antibody Discovery, and Targeted Protein Degradation (TPD). The company maintains a robust pipeline with multiple assets in Phase III trials or at the NDA stage. Evopoint is recognized for its 'Global First-in-class' and 'Best-in-class' strategy, supported by an integrated R&D ecosystem that spans from early discovery to global commercialization. It has secured significant international recognition through high-value licensing deals with global pharmaceutical leaders.